Neuroendocrine tumors of the small intestine: presentation of a clinical case and literature review
Abstract
The prevalence of neuroendocrine tumors (NET) has increased over the past few decades, probably due to early diagnosis, increased alertness and widespread endoscopic and imaging studies in the diagnosis of diseases of the gastrointestinal tract (GIT). Neuroendocrine tumors that occur in the small intestine are considered rare malignancies. Despite this, both the incidence and prevalence of NET of the small intestine are gradually increasing. According to retrospective studies, the standardized incidence rate of small intestine NET was 1.46 per 100,000 populations in 2018, equaling the incidence of lung NET. To date, there are no statistics on the incidence of NET in the Russian Federation. This makes it difficult to analyze the results of treatment and to develop a diagnostic algorithm.
The work analyzes the data of newest publications on the clinical manifestations of NET of the small intestine, the main diagnostic and therapeutic methods used in this pathology and presents a clinical case of small intestine NET.
Conclusion. In the early stages of the disease, most patients have slight symptoms or none at all.
About the Authors
E. V. Fedotova
ГБУЗ АО «Северодвинская городская клиническая больница №2 скорой медицинской помощи»; ФГБОУ ВО «Северный государственный медицинский университет» Минздрава Росси
Russian Federation
Russian Federation
A. L. Petrushin
ГБУЗ АО «Карпогорская ЦРБ»
Russian Federation
Russian Federation
M. N. Nechaeva
ГБУЗ АО «Северодвинская городская клиническая больница №2 скорой медицинской помощи»
Russian Federation
Russian Federation
O. A. Shangin
ГБУЗ АО «Северодвинская городская клиническая больница №2 скорой медицинской помощи»
Russian Federation
Russian Federation
M. Yu. Valkov
ФГБОУ ВО «Северный государственный медицинский университет» Минздрава России
Russian Federation
Russian Federation
References
1. Klinicheskie rekomendacii. Nejroendokrinnye opuholi (Clinical recommendations. Neuroendocrine tumors). Moskva, 2020:54 (in Russ.)
2. Rindi G, Bordi C, Rappel S. [et al.] Gastric carcinoids and neuroendocrine carcinomas: pathogenesis, pathology, and behavior. World J Surg. 1996; (2):168–72. (in Engl) doi: 10.1007/s002689900026
3. Dasari A, Shen C, Halperin D. [et al.] Trends in the Incidence, Prevalence, and Survival Outcomes in Patients with Neuroendocrine Tumors in the United States. JAMA Oncol. 2017; (3): 1335–1342. (in Engl) doi: 10.1001/jamaoncol.2017.0589
4. Sorbye H, Grande E, Pavel M. [et al.] European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for digestive neuroendocrine carcinoma. J Neuroendocrinol. 2023; 35(3): e13249. (in Engl) doi: 10.1111/jne.13249.
5. Fraenkel M, Kim M, Faggiano A. [et al.]. Incidence of gastroenteropancreatic neuroendocrine tumours: a systematic review of the literature. Endocr Relat Cancer. 2014; 21(3): R153–R163. (in Engl) doi: 10.1530/ERC-13-0125.
6. White BE, Rous B, Chandrakumaran K. [et al.] Incidence and survival of neuroendocrine neoplasia in England 1995–2018: a retrospective, population-based study. Lancet Reg Health Eur. 2022; (23):100510. (in Engl) doi: 10.1016/j.lanepe.2022.100510
7. Grozinsky-Glasberg S, Davar J, Hofland J. [et al.] European Neuroendocrine Tumor Society (ENETS) 2022 guidance paper for carcinoid syndrome and carcinoid heart disease. J Neuroendocrinol. 2022; 34(7): e13146. (in Engl) doi: 10.1111/jne.13146.
8. Ahmed M. Gastrointestinal neuroendocrine tumors in 2020. World J Gastrointest Oncol. 2020; 12(8): 791–807. (in Engl)
9. Maggard MA, O'Connell JB, Ko CY. Updated population-based review of carcinoid tumors. Ann Surg 2004; 240: 117–122. (in Engl)
10. Modlin IM, Kidd M, Latich I. [et al.] Current status of gastrointestinal carcinoids. Gastroenterology 2005; 128: 1717–1751 (in Engl)
11. Moertel CG. Karnofsky memorial lecture. An odyssey in the land of small tumors. J Clin Oncol. 1987; 5: 1502–1522. (in Engl)
12. Taghavi S, Jayarajan SN, Powers BD. [et al.] Examining rectal carcinoids in the era of screening colonoscopy: a surveillance, epidemiology, and end results analysis. Dis Colon Rectum. 2013; 56: 952-959 (in Engl) doi: 10.1097/DCR.0b013e318291f512
13. Kim JY, Hong SM, Ro JY. Recent updates on grading and classification of neuroendocrine tumors. Ann Diagn Pathol. 2017; 29:11–16. (in Engl) doi: 10.1016/j.anndiagpath.2017.04.005.
14. Capdevila J, Meeker A, García-Carbonero R. [et al.] Molecular biology of neuroendocrine tumors: from pathways to biomarkers and targets. Cancer Metastasis Rev. 2014; 33:345–351. (in Engl) doi: 10.1007/s10555-013-9468-y.
15. Blažević A, Hofland J, Hofland LJ [et al.] Small intestinal neuroendocrine tumours and fibrosis: an entangled conundrum. Endocr Relat Cancer. 2018; 25: R115-R130. (in Engl) doi: 10.1530/ERC-17-0380.
16. Kidd M, Modlin I, Shapiro M. [et al.] CTGF, intestinal stellate cells and carcinoid fibrogenesis. World J Gastroenterol. 2007; 13:5208–5216. (in Engl) doi: 10.3748/wjg.v13.i39.5208.
17. Cives M, Pelle' E, Quaresmini D [et al.] The Tumor Microenvironment in Neuroendocrine Tumors: Biology and Therapeutic Implications. Neuroendocrinology. 2019; 109:83–99. (in Engl) doi: 10.1159/000497355.
18. Cives M, Strosberg JR. Gastroenteropancreatic Neuroendocrine Tumors. CA Cancer J Clin. 2018; 68:471–487. (in Engl) doi: 10.3322/caac.21493.
19. da Silva A, Bowden M, Zhang S. [et al.] Characterization of the Neuroendocrine Tumor Immune Microenvironment. Pancreas. 2018; 47:1123–1129. (in Engl) doi: 10.1097/MPA.0000000000001150.
20. Krug S, Abbassi R, Griesmann H. [et al.] Therapeutic targeting of tumor-associated macrophages in pancreatic neuroendocrine tumors. Int J Cancer. 2018; 143:1806–1816. (in Engl) doi: 10.1002/ijc.31562.
21. Sata N, Tsukahara M, Koizumi M. [et al.] Primary small-cell neuroendocrine carcinoma of the duodenum - a case report and review of literature. World J Surg Oncol. 2004; 2:28. (in Engl)
22. Burke AP, Thomas RM, Elsayed AM, Sobin LH. Carcinoids of the jejunum and ileum: an immunohistochemical and clinicopathologic study of 167 cases. Cancer. 1997; 79:1086–1093 (in Engl)
23. Klöppel G, Perren A, Heitz PU. The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification. Ann N Y Acad Sci. 2004; 1014:13–27. (in Engl) doi: 10.1196/annals.1294.002.
24. Pasieka JL. Carcinoid tumors. Surg Clin North Am. 2009; 89:1123–1137. (in Engl) doi: 10.1016/j.suc.2009.06.008.
25. Druce MR, Bharwani N, Akker SA. [et al.] Intra-abdominal fibrosis in a recent cohort of patients with neuroendocrine ('carcinoid') tumours of the small bowel. QJM. 2010; 103:177–185. (in Engl) doi:10.1093/qjmed/hcp191.
26. Daskalakis K, Karakatsanis A, Stålberg P. [et al.] Clinical signs of fibrosis in small intestinal neuroendocrine tumours. Br J Surg. 2017; 104:69–75. (in Engl) doi: 10.1002/bjs.10333.
27. Bösch F, Bruewer K, D'Anastasi M [et al.] Neuroendocrine tumors of the small intestine causing a desmoplastic reaction of the mesentery are a more aggressive cohort. Surgery. 2018; 164:1093–1099. (in Engl) doi: 10.1016/j.surg.2018.06.026.
28. Ramirez RA, Beyer DT, Chauhan A. [et al.] The Role of Capecitabine/Temozolomide in Metastatic Neuroendocrine Tumors. Oncologist. 2016; 21:671–675. (in Engl) doi: 10.1634/theoncologist.2015-0470.
29. Ilett EE, Langer SW, Olsen IH [et al.] Neuroendocrine Carcinomas of the Gastroenteropancreatic System: A Comprehensive Review. Diagnostics (Basel). 2015; 5:119–176. 10.3390/diagnostics5020119. (in Engl)
30. Woodside KJ, Townsend CM, Mark Evers B. Current management of gastrointestinal carcinoid tumors. J Gastrointest Surg. 2004; 8:742–756. (in Engl) doi: 10.1016/j.gassur.2004.04.010.
31. Fox DJ, Khattar RS. Carcinoid heart disease: presentation, diagnosis, and management. Heart. 2004; 90:1224–1228. (in Engl) doi: 10.1136/hrt.2004.040329.
32. Bhattacharyya S, Toumpanakis C, Caplin ME, Davar J. Usefulness of N-terminal pro-brain natriuretic peptide as a biomarker of the presence of carcinoid heart disease. Am J Cardiol. 2008; 102:938–942. (in Engl) doi: 10.1016/j.amjcard.2008.05.047.
Review
For citations:
Fedotova E.V., Petrushin A.L., Nechaeva M.N., Shangin O.A., Valkov M.Yu. Neuroendocrine tumors of the small intestine: presentation of a clinical case and literature review. Bashkortostan Medical Journal. 2025;20(1):111-120. (In Russ.)
Views:
11
Email this article 
